The role of cytotoxic chemotherapy in prostate cancer: A critical reevaluation 20 years later

Research output: Contribution to journalArticle

Abstract

In this review, we describe how clinical investigators addressed some of the challenges in prostate cancer chemotherapy trials 20 years ago, and we indicate what has evolved in the field since that time. We consider the impact that prostate-specific antigen measurement had in this setting, evolving clinical paradigms, multidisciplinary programs, and the current armamentarium of cancer treatment, including targeted molecular therapy, for patients with hormone-refractory disease.

Original languageEnglish (US)
Pages (from-to)853-862
Number of pages10
JournalOncology
Volume20
Issue number8
StatePublished - 2006

Fingerprint

Molecular Targeted Therapy
Prostate-Specific Antigen
Prostatic Neoplasms
Research Personnel
Hormones
Drug Therapy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

The role of cytotoxic chemotherapy in prostate cancer : A critical reevaluation 20 years later. / Eisenberger, Mario; Sinibaldi, Victoria.

In: Oncology, Vol. 20, No. 8, 2006, p. 853-862.

Research output: Contribution to journalArticle

@article{61af832468ef4a2782dee7fc91e86e5a,
title = "The role of cytotoxic chemotherapy in prostate cancer: A critical reevaluation 20 years later",
abstract = "In this review, we describe how clinical investigators addressed some of the challenges in prostate cancer chemotherapy trials 20 years ago, and we indicate what has evolved in the field since that time. We consider the impact that prostate-specific antigen measurement had in this setting, evolving clinical paradigms, multidisciplinary programs, and the current armamentarium of cancer treatment, including targeted molecular therapy, for patients with hormone-refractory disease.",
author = "Mario Eisenberger and Victoria Sinibaldi",
year = "2006",
language = "English (US)",
volume = "20",
pages = "853--862",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - The role of cytotoxic chemotherapy in prostate cancer

T2 - A critical reevaluation 20 years later

AU - Eisenberger, Mario

AU - Sinibaldi, Victoria

PY - 2006

Y1 - 2006

N2 - In this review, we describe how clinical investigators addressed some of the challenges in prostate cancer chemotherapy trials 20 years ago, and we indicate what has evolved in the field since that time. We consider the impact that prostate-specific antigen measurement had in this setting, evolving clinical paradigms, multidisciplinary programs, and the current armamentarium of cancer treatment, including targeted molecular therapy, for patients with hormone-refractory disease.

AB - In this review, we describe how clinical investigators addressed some of the challenges in prostate cancer chemotherapy trials 20 years ago, and we indicate what has evolved in the field since that time. We consider the impact that prostate-specific antigen measurement had in this setting, evolving clinical paradigms, multidisciplinary programs, and the current armamentarium of cancer treatment, including targeted molecular therapy, for patients with hormone-refractory disease.

UR - http://www.scopus.com/inward/record.url?scp=34250684840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250684840&partnerID=8YFLogxK

M3 - Article

C2 - 16922258

AN - SCOPUS:34250684840

VL - 20

SP - 853

EP - 862

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 8

ER -